APA (7th ed.) Citation

Huntington, J. A., Yu, B., Li, L., Jensen, E., Bruno, C., & Rhee, E. G. (2019). 2227. Outcomes in Patients with Renal Impairment from a Phase 3 Clinical Trial for Ceftolozane–Tazobactam (C/T) Treatment of Nosocomial Pneumonia (ASPECT-NP). Open Forum Infectious Diseases, 6, S760. https://doi.org/10.1093/ofid/ofz360.1905

Chicago Style (17th ed.) Citation

Huntington, Jennifer A., Brian Yu, Linping Li, Erin Jensen, Christopher Bruno, and Elizabeth G. Rhee. "2227. Outcomes in Patients with Renal Impairment from a Phase 3 Clinical Trial for Ceftolozane–Tazobactam (C/T) Treatment of Nosocomial Pneumonia (ASPECT-NP)." Open Forum Infectious Diseases 6 (2019): S760. https://doi.org/10.1093/ofid/ofz360.1905.

MLA (9th ed.) Citation

Huntington, Jennifer A., et al. "2227. Outcomes in Patients with Renal Impairment from a Phase 3 Clinical Trial for Ceftolozane–Tazobactam (C/T) Treatment of Nosocomial Pneumonia (ASPECT-NP)." Open Forum Infectious Diseases, vol. 6, 2019, p. S760, https://doi.org/10.1093/ofid/ofz360.1905.